

# Samer Gawrieh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3380323/publications.pdf>

Version: 2024-02-01

58  
papers

1,690  
citations

361413

20  
h-index

315739

38  
g-index

58  
all docs

58  
docs citations

58  
times ranked

2310  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of High-risk Nonalcoholic Steatohepatitis (NASH) in the United States: Results From NHANES 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 115-124.e7.	4.4	25
2	High-quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population. <i>Hepatology</i> , 2022, 75, 1491-1506.	7.3	99
3	Severe Alcohol-Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure. <i>Hepatology Communications</i> , 2022, 6, 1090-1099.	4.3	7
4	Validation of the accuracy of the FAST-1 score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. <i>PLoS ONE</i> , 2022, 17, e0266859.	2.5	20
5	Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. <i>Liver International</i> , 2021, 41, 996-1011.	3.9	16
6	A perspective on RNA interference-based therapeutics for metabolic liver diseases. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 237-244.	4.1	7
7	Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial. <i>Hepatology Communications</i> , 2021, 5, 786-797.	4.3	12
8	Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. <i>Journal of Clinical Lipidology</i> , 2021, 15, 275-291.	1.5	8
9	Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 709-719.	2.4	8
10	Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G439-G449.	3.4	18
11	Saroglitazar, a PPAR- $\alpha/\beta$ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. <i>Hepatology</i> , 2021, 74, 1809-1824.	7.3	163
12	Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. <i>Journal of Pediatrics</i> , 2021, 239, 161-167.e5.	1.8	8
13	Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. <i>Journal of Hepatology</i> , 2021, 75, 284-291.	3.7	124
14	Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00420.	2.5	6
15	Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 495-509.	7.3	117
16	Apolipoprotein B and PNPLA3 Double Heterozygosity in a Father-Son Pair With Advanced Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 71, 383-385.	7.3	4
17	Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. <i>American Journal of Gastroenterology</i> , 2020, 115, 1486-1495.	0.4	27
18	Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort. <i>Hepatology Communications</i> , 2020, 4, 1708-1716.	4.3	11

#	ARTICLE	IF	CITATIONS
19	Decreased Quality of Life Is Significantly Associated With Body Composition in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2980-2988.e4.	4.4	19
20	Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2020, 72, 785-785.	7.3	0
21	Multicenter Validation of Association Between Decline in MRIâ€PDDF and Histologic Response in NASH. <i>Hepatology</i> , 2020, 72, 1219-1229.	7.3	79
22	Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00139.	2.5	4
23	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. <i>Annals of Diagnostic Pathology</i> , 2020, 47, 151518.	1.3	37
24	Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1307, 417-440.	1.6	21
25	ADH1Bâ€—2 Is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. <i>Gastroenterology</i> , 2020, 159, 929-943.	1.3	18
26	Clinical characteristics and outcomes of mild to moderate alcoholic hepatitis. <i>GastroHep</i> , 2019, 1, 161-165.	0.6	6
27	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	3.7	77
28	Longâ€term metformin use may improve clinical outcomes in diabetic patients with nonâ€alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 317-328.	3.7	52
29	A Pilot Genomeâ€Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. <i>Hepatology Communications</i> , 2019, 3, 1571-1584.	4.3	16
30	Is Fasting Necessary for Individuals With Nonalcoholic Fatty Liver Disease to Undergo Vibration-Controlled Transient Elastography?. <i>American Journal of Gastroenterology</i> , 2019, 114, 995-997.	0.4	15
31	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. <i>American Journal of Gastroenterology</i> , 2019, 114, 1626-1635.	0.4	65
32	Older Age and Disease Duration Are Highly Associated with Hepatocellular Carcinoma in Patients with Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1705-1710.	2.3	8
33	Primate fetal hepatic responses to maternal obesity: epigenetic signalling pathways and lipid accumulation. <i>Journal of Physiology</i> , 2018, 596, 5823-5837.	2.9	51
34	Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. <i>Clinics in Liver Disease</i> , 2018, 22, 189-199.	2.1	24
35	Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. <i>Drugs and Aging</i> , 2018, 35, 589-602.	2.7	12
36	Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development. <i>Epigenetics</i> , 2018, 13, 605-626.	2.7	13

#	ARTICLE	IF	CITATIONS
37	Lower expression of tumor microRNAâ€26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment. <i>Journal of Surgical Oncology</i> , 2018, 118, 431-439.	1.7	6
38	Proteomic characterization of high-density lipoprotein particles in patients with non-alcoholic fatty liver disease. <i>Clinical Proteomics</i> , 2018, 15, 10.	2.1	23
39	Automated assessment of steatosis in murine fatty liver. <i>PLoS ONE</i> , 2018, 13, e0197242.	2.5	18
40	Function of inhibitor of Bruton's tyrosine kinase isoform Î± (IBTKÎ±) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response. <i>Journal of Biological Chemistry</i> , 2017, 292, 14050-14065.	3.4	14
41	Management of Difficult Cases of Autoimmune Hepatitis. <i>Current Gastroenterology Reports</i> , 2016, 18, 9.	2.5	13
42	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016, 9, 26-40.	3.1	11
43	Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. <i>Human Pathology</i> , 2015, 46, 767-775.	2.0	33
44	Sex Hormones, Sex Hormone-Binding Globulin, and Liver Fat: Which Came First, the Chicken or the Egg?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1694-1696.	4.4	6
45	Pharmacotherapy for Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2015, 35, 338-348.	3.6	27
46	Automatic classification of white regions in liver biopsies by supervised machine learning. <i>Human Pathology</i> , 2014, 45, 785-792.	2.0	69
47	NAFLD Fibrosis Score: Is It Ready for Wider Use in Clinical Practice and for Clinical Trials?. <i>Gastroenterology</i> , 2013, 145, 717-719.	1.3	9
48	Genetic Variation in the Peroxisome Proliferator Activated Receptor-Gamma Gene Is Associated with Histologically Advanced NAFLD. <i>Digestive Diseases and Sciences</i> , 2012, 57, 952-957.	2.3	44
49	Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology. <i>Annals of Diagnostic Pathology</i> , 2011, 15, 19-24.	1.3	72
50	A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. <i>Obesity Surgery</i> , 2010, 20, 685-691.	2.1	55
51	Hepatic Gene Networks in Morbidly Obese Patients With Nonalcoholic Fatty Liver Disease. <i>Obesity Surgery</i> , 2010, 20, 1698-1709.	2.1	32
52	Swallow Syncope in Association with Schatzki Ring and Hypertensive Esophageal Peristalsis: Report of Three Cases and Review of the Literature. <i>Dysphagia</i> , 2005, 20, 273-277.	1.8	17
53	Variceal band ligation versus propranolol for primary prophylaxis of variceal bleeding in cirrhosis. <i>Current Gastroenterology Reports</i> , 2005, 7, 175-6.	2.5	1
54	Treatment of actively bleeding Mallory-Weiss syndrome: epinephrine injection or band ligation?. <i>Current Gastroenterology Reports</i> , 2005, 7, 175.	2.5	0

#	ARTICLE	IF	CITATIONS
55	Management of esophageal varices: An update from Digestive Disease Week and American Association for the Study of Liver Diseases 2003. Current Gastroenterology Reports, 2004, 6, 206-209.	2.5	1
56	Oxidative Stress in Nonalcoholic Fatty Liver Disease: Pathogenesis and Antioxidant Therapies. Journal of Investigative Medicine, 2004, 52, 506-514.	1.6	30
57	Medical Management of Nocturnal Symptoms of Gastro-Oesophageal Reflux Disease in the Elderly. Drugs and Aging, 2003, 20, 509-516.	2.7	8
58	Peripheral mechanisms affecting the lower esophageal sphincter tone. Gastroenterology Clinics of North America, 2002, 31, S21-S33.	2.2	4